India, Aug. 5 -- Novo Nordisk A/S (NVO) said Wednesday it secured a preliminary injunction from the District Court of The Hague against Ceban Ziekenhuisfarmacie B.V., ordering the company to immediately stop selling a compounded semaglutide nasal spray that the court found infringes Novo Nordisk's supplementary protection certificate covering semaglutide.
The court also ordered Ceban to remove references to the product from relevant listings and websites, disclose information about its commercial supply chain, and reimburse Novo Nordisk's legal costs.
Novo Nordisk said the ruling protects patients from unapproved semaglutide formulations and reinforces regulatory standards for medicine quality, safety and efficacy.
"Protecting patients m...